Table 1.
Extracted data of included studies.
| Reference | Method | Number | Age | Male% | Follow-up (months) | Tumor type | Outcomes |
|---|---|---|---|---|---|---|---|
| Ding et al. (14) | IHC>10% | 238 | 68 (Median) | 81.9 | 47 (median) | non-muscle-invasive bladder cancer (NMIBC) | Tumor size; recurrence; progression; grade |
| Kolla et al. (15) | IHC>10% | 90 | 58 (mean) | 95.6 | 46 (median) | muscle invasive urinary bladder cancer | grade; lymph node metastasis |
| Krüger et al. (16) | IHC>10% | 138 | 64 (Median) | 80.4 | 53 (mean) | muscle-invasive bladder carcinoma | grade; lymph node metastasis |
| Lim et al. (17) | IHC≥50% | 141 | 68.9 (mean) | 86.5 | 73.3 (mean) | non-muscle-invasive bladder cancer | progression; recurrence; tumor size; grade |
| Hegazy et al. (18) | IHC>20% | 88 | not specific | not specific | 36 (median) | non-muscle invasive (NMI) bladder cancer | tumor recurrence and progression; grade |
| Paul et al. (19) | IHC>30% | 178 | 71 (mean) | not specific | 82 (mean) | non-muscle-invasive bladder cancer | Recurrence; progression |
| El et al. (20) | IHC>30% | 103 | 63 (Median) | 93.2 | not specific | non-muscle-invasive and muscle-invasive bladder cancer | Tumor size; Tumor grade |
| Inoue et al. (21) | IHC>10% | 95 | not specific | 72.6 | 36 (median) | muscle-invasive bladder carcinoma | recurrence condition |
| Behnsawy et al. (22) | IHC>10% | 161 | not specific | 85.1 | not specific | non-muscle-invasive bladder cancer | recurrence condition |
| Olsson et al. (23) | IHC>30% | 201 | 73 (Median) | 83 | 58 (median) | non-muscle-invasive bladder cancer | tumor size, multiplicity, possible presence of histologically proven recurrence and progression; grade |
| Moustakas et al. (24) | IHC>10% | 48 | 68 (mean) | 97.3 | not specific | non-muscle-invasive urothelial cell carcinoma of the bladder | Grade at diagnosis; recurrence-free survival (RFS) |
| Soria et al. (25) | IHC>30% | 354 | 66.3 (Median) | 81 | 123 (mean) | muscle invasive and very high-risk non–muscle invasive bladder cancer | oncological outcomes; grade |
| Bolenz et al. (26) | IHC>10% | 198 | 66.7 (Median) | 78.8 | 48.7 (mean) | non-muscle-invasive and muscle-invasive bladder cancer | recurrence; lymph node metastasis; grade |
| Abdelrahman et al. (27) | IHC>30% | 60 | 52 (Median) | 71.70 | 44(mean) | Non-muscle-invasive bladder cancer (NMIBC) | tumor recurrence, progression, recurrence-free survival (RFS) and progression-free survival (PFS); grade |
IHC, immunohistochemistry.